April 2 (Reuters) - Mesa Laboratories Inc MLAB.O :
* MESA LABORATORIES: TO RECORD NON-CASH IMPAIRMENT LOSSES
RELATED
TO CLINICAL GENOMICS & BIOPHARMACEUTICAL DEVELOPMENT UNITS OF
$271 MILLION IN Q4 OF 2024
* MESA LABORATORIES INC: EXPECT UNAUDITED RESULTS FOR Q4 OF
2024
WILL INCLUDE NON-CASH IMPAIRMENT LOSSES OF ABOUT$123 MILLION
RELATED TO GOODWILL
* MESA LABORATORIES INC: EXPECT TO RECORD NON-CASH
IMPAIRMENT
LOSSES TO OTHER INTANGIBLE ASSETS OF ABOUT $148 MILLION
* MESA LABORATORIES INC: NON-CASH ACCOUNTING CHARGES ARE NOT
EXPECTED TO IMPACT CASH FLOWS FROM CURRENT OR FUTURE OPERATIONS
Source text for Eikon: ID:n0001437749-24-010537
Further company coverage: MLAB.O
((Reuters.Briefs@thomsonreuters.com;))